Multidrug-resistant Acinetobacter spp.: Increasingly problematic nosocomial pathogens

Yonsei Medical Journal

Volumn 52, Issue 6, 2011, Pages 879-891

  Lee, Kyungwon ^a   Yong, Dongeun ^a   Jeong, Seok Hoon ^a   Chong, Yunsop ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Acinetobacter baumannii; Metallo lactamase; Multidrug resistance; OXA type carbapenemase

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; COLISTIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; METALLO BETA LACTAMASE; PIPERACILLIN; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DISEASE SURVEILLANCE; ENTEROBACTERIACEAE; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; KOREA; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; TAXONOMY; TERTIARY HEALTH CARE;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL;

EID: 80055023981     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2011.52.6.879     Document Type: Article

References (94)

1. Salyers AA, Whitt DD. Revenge of the microbes: how bacterial resistance is undermining the antibiotic miracle. Washington, DC: ASM Press; 2005.
2. Brötz-Oesterhelt H, Sass P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol 2010;5:1553-79.
3. Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009;59 Suppl 1:S4-16.
4. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602.
5. Marchaim D, Zaidenstein R, Lazarovitch T, Karpuch Y, Ziv T, Weinberger M. Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotics resistance, and patient age. Eur J Clin Microbiol Infect Dis 2008;27:1045-51.
6. Ho J, Tambyah PA, Paterson DL. Multiresistant Gram-negative infections: a global perspective. Curr Opin Infect Dis 2010;23: 546-53.
7. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254-63.
8. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-65.
9. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008;358:1271-81.
10. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538-82
11. Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents 2011;37:291-5.
12. Nemec A, Krizova L, Maixnerova M, van der Reijden TJ, Deschaght P, Passet V, et al. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Res Microbiol 2011;162:393-404.
13. Bouvet PJ, Grimont PA. Identification and biotyping of clinical isolates of Acinetobacter. Ann Inst Pasteur Microbiol 1987;138: 569-78.
14. Dortet L, Legrand P, Soussy CJ, Cattoir V. Bacterial identification, clinical significance, and antimicrobial susceptibilities of Acinetobacter ursingii and Acinetobacter schindleri, two frequently misidentified opportunistic pathogens. J Clin Microbiol 2006;44: 4471-8.
15. Lee Y, Lee J, Jeong SH, Lee J, Bae IK, Lee K. Carbapenem-non-susceptible Acinetobacter baumannii of sequence type 92 or its single-locus variants with a G428T substitution in zone 2 of the rpoB gene. J Antimicrob Chemother 2011;66:66-72.
16. Wendt C, Dietze B, Dietz E, Rüden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 1997;35:1394-7.
17. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 1998;36:1938-41.
18. Getchell-White SI, Donowitz LG, Gröschel DH. The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol 1989;10:402-7.
19. Petersen K, Cannegieter SC, van der Reijden TJ, van Strijen B, You DM, Babel BS, et al. Diversity and clinical impact of Acinetobacter baumannii colonization and infection at a military medical center. J Clin Microbiol 2011;49:159-66.
20. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011.
21. Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, et al. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR Study 2009. Yonsei Med J 2011;52:793-802.
22. Wu CJ, Lee HC, Lee NY, Shih HI, Ko NY, Wang LR, et al. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003. J Microbiol Immunol Infect 2006;39:135-43.
23. Song JY, Cheong HJ, Choi WS, Heo JY, Noh JY, Kim WJ. Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections. J Med Microbiol 2011;60:605-11.
24. Kim JW, Heo ST, Jin JS, Choi CH, Lee YC, Jeong YG, et al. Characterization of Acinetobacter baumannii carrying blaOXA-23, blaPER-1 and armA in a Korean hospital. Clin Microbiol Infect 2008;14: 716-8.
25. Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006;5:2.
26. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315-7.
27. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86.
28. Bauernfeind A, Chong Y, Schweighart S. Extended broad spectrum β-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection 1989;17:316-21.
29. Kim J, Kwon Y, Pai H, Kim JW, Cho DT. Survey of Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: prevalence of SHV-12 and SHV-2a in Korea. J Clin Microbiol 1998;36:1446-9.
30. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45:1151-61.
31. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009;53:5046-54.
32. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010;362:1804-13.
33. Vila J, Martí S, Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007;59:1210-5.
34. Hujer KM, Hamza NS, Hujer AM, Perez F, Helfand MS, Bethel CR, et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother 2005;49:2941-8.
35. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother 2003;52:629-35.
36. Lin YC, Hsia KC, Chen YC, Sheng WH, Chang SC, Liao MH, et al. Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. Antimicrob Agents Chemother 2010;54:2078-84.
37. Lee Y, Kim CK, Lee H, Jeong SH, Yong D, Lee K. A novel insertion sequence, ISAba10, inserted into ISAba1 adjacent to the blaOXA-23 gene and disrupting the outer membrane protein gene carO in Acinetobacter baumannii. Antimicrob Agents Chemother 2011;55: 361-3.
38. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006;2:e7.
39. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006;55:1619-29.
40. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007;45:1179-81.
41. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010;16:209-15.
42. Lee K, Lee MA, Lee CH, Lee J, Roh KH, Kim S, et al. Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneu moniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007. Yonsei Med J 2010;51:901-11.
43. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003;41:3542-7.
44. Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand Y, Labia R. Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993;37:962-9.
45. Yong D, Shin JH, Kim S, Lim Y, Yum JH, Lee K, et al. High prevalence of PER-1 extended-spectrum β-lactamase-producing Acinetobacter spp. in Korea. Antimicrob Agents Chemother 2003;47:1749-51.
46. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010;54:969-76.
47. Lee K, Lim JB, Yum JH, Yong D, Chong Y, Kim JM, et al. blaVIM-2 cassette-containing novel integrons in metallo-β-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother 2002;46:1053-8.
48. Yum JH, Yi K, Lee H, Yong D, Lee K, Kim JM, et al. Molecular characterization of metallo-β-lactamase-producing Acinetobacter baumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the blaVIM-2 gene cassettes. J Antimicrob Chemother 2002;49:837-40.
49. Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, et al. Novel acquired metallo-β-lactamase gene, blaSIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother 2005;49:4485-91.
50. Sung JY, Kwon KC, Park JW, Kim YS, Kim JM, Shin KS, et al. Dissemination of IMP-1 and OXA type β-lactamase in carbapenem-resistant Acinetobacter baumannii. Korean J Lab Med 2008; 28:16-23.
51. Lim YM, Shin KS, Kim J. Distinct antimicrobial resistance patterns and antimicrobial resistance-harboring genes according to genomic species of Acinetobacter isolates. J Clin Microbiol 2007;45:902-5.
52. Lee JH, Choi CH, Kang HY, Lee JY, Kim J, Lee YC, et al. Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU. J Antimicrob Chemother 2007;59:633-9.
53. Lee K, Kim MN, Choi TY, Cho SE, Lee S, Whang DH, et al. Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea. Int J Antimicrob Agents 2009;33:520-4.
54. Brown S, Amyes S. OXA β-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 2006;57:1-3.
55. Jeon BC, Jeong SH, Bae IK, Kwon SB, Lee K, Young D, et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 β-lactamase in Korea. J Clin Microbiol 2005;43:2241-5.
56. Yang HY, Lee HJ, Suh JT, Lee KM. Outbreaks of imipenem resistant Acinetobacter baumannii producing OXA-23 β-lactamase in a tertiary care hospital in Korea. Yonsei Med J 2009;50:764-70.
57. Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y; Korean Nationwide Surveillance of Antimicrobial Resistance Group. VIM- and IMP-type metallo-β-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg Infect Dis 2003;9: 868-71.
58. Kim CK, Lee Y, Lee H, Woo GJ, Song W, Kim MN, et al. Prevalence and diversity of carbapenemases among imipenem-nonsusceptible Acinetobacter isolates in Korea: emergence of a novel OXA-182. Diagn Microbiol Infect Dis 2010;68:432-8.
59. Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. OXA-143, a novel carbapenem-hydrolyzing class D β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2009;53: 5035-8.
60. Lin MF, Kuo HY, Yeh HW, Yang CM, Sung CH, Tu CC, et al. Emergence and dissemination of blaOXA-23-carrying imipenem-resistant Acinetobacter sp in a regional hospital in Taiwan. J Microbiol Immunol Infect 2011;44:39-44.
61. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother 2009;63:55-9.
62. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993;57:138-63.
63. Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006;50:4114-23.
64. Lee H, Yong D, Yum JH, Roh KH, Lee K, Yamane K, et al. Dissemination of 16S rRNA methylase-mediated highly amikacin-resistant isolates of Klebsiella pneumoniae and Acinetobacter baumannii in Korea. Diagn Microbiol Infect Dis 2006;56:305-12.
65. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999;2:38-55.
66. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. Int J Antimicrob Agents 2002;19:21-31.
67. Koo SH, Kwon KC, Cho HH, Sung JY. Genetic basis of multidrug-resistant Acinetobacter baumannii clinical isolates from three university hospitals in Chungcheong Province, Korea. Korean J Lab Med 2010;30:498-506.
68. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998;351:797-9.
69. Touati A, Brasme L, Benallaoua S, Gharout A, Madoux J, De Champs C. First report of qnrB-producing Enterobacter cloacae and qnrA-producing Acinetobacter baumannii recovered from Algerian hospitals. Diagn Microbiol Infect Dis 2008;60:287-90.
70. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009;22:664-89.
71. Wang YF, Dowzicky MJ. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008. Diagn Microbiol Infect Dis 2010;68:73-9.
72. Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 2008;52:557-62.
73. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007;60:317-22.
74. Park YK, Choi JY, Song JH, Ko KS. In vitro activity of tigecycline against colistin-resistant Acinetobacter spp. isolates from Korea. Int J Antimicrob Agents 2009;33:289-90.
75. Arroyo LA, Mateos I, González V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009;53: 1295-6.
76. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59: 128-31.
77. Roh KH, Kim CK, Yum JH, Yong D, Jeong SH, Lim CS, et al. Carbapenem Resistance Mechanisms and Molecular Epidemiology of Acinetobacter spp. from Four Hospitals in Seoul and Gyeonggi Province in 2006. Korean J Clin Microbiol 2010;13:27-33.
78. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007;60:1163-7.
79. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009;53:3628-34.
80. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010;54:4971-7.
81. Sykes R. The 2009 Garrod lecture: the evolution of antimicrobial resistance: a Darwinian perspective. J Antimicrob Chemother 2010;65:1842-52.
82. Talbot GH. The antibiotic development pipeline for multidrug-resistant gram-negative bacilli: current and future landscapes. Infect Control Hosp Epidemiol 2010;31 Suppl 1:S55-8.
83. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005;18:638-56.
84. Fishman N. Antimicrobial stewardship. Am J Med 2006;119:S53-61.
85. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003;36:S11-23.
86. Kwak YG, Cho YK, Kim JY, Lee SO, Kim HY, Kim YK, et al. Korean Nosocomial Infections Surveillance System, Intensive Care Unit Module Report: Data Summary from July 2008 through June 2009 and Analysis of 3-Year Results. Korean J Nosocomial Infect Control 2010;15:14-25.
87. Lu PL, Doumith M, Livermore DM, Chen TP, Woodford N. Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob Chemother 2009;63:641-7.
88. Peterson LR, Diekema DJ. To screen or not to screen for methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2010;48: 683-9.
89. Carlet J, Fabry J, Amalberti R, Degos L. The "zero risk" concept for hospital-acquired infections: a risky business! Clin Infect Dis 2009;49:747-9.
90. Yuji K, Oiso G, Matsumura T, Murashige N, Kami M. Police investigation into multidrug-resistant Acinetobacter baumannii outbreak in Japan. Clin Infect Dis 2011;52:422.
91. Song JH, Jung KS, Kang MW, Kim DJ, Pai H, Suh GY, et al. Treatment Guidelines for Community-acquired Pneumonia in Korea: An Evidence-based Approach to Appropriate Antimicrobial Therapy. Tuberc Respir Dis 2009;67:281-302.
92. Park S, Soumerai SB, Adams AS, Finkelstein JA, Jang S, Ross-Degnan D. Antibiotic use following a Korean national policy to prohibit medication dispensing by physicians. Health Policy Plan 2005;20:302-9.
93. Metlay JP, Shea JA, Crossette LB, Asch DA. Tensions in antibiotic prescribing: pitting social concerns against the interests of individual patients. J Gen Intern Med 2002;17:87-94.
94. Liew YX, Lee W, Kwa AL, Lye DC, Yeo CL, Hsu LY. Inappropriate carbapenem use in Singapore public hospitals: opportunities for antimicrobial stewardship. Int J Antimicrob Agents 2011;37: 87-8.